06:24 AM EDT, 09/18/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said late Wednesday that data from a phase 3 trial of once-daily oral semaglutide 25-milligram pill showed an average weight loss of 16.6% in participants who adhered to the treatment, compared with 2.7% for placebo.

The company said that 34.4% of participants lost at least 20% of body weight, versus just 2.9% on placebo.

Even with varied adherence, results showed an average weight loss of 13.6%, the company said, adding that the oral pill also improved cardiovascular risk factors and daily activity levels, mirroring benefits previously observed with the injectable version, Wegovy.

Novo Nordisk ( NVO ) shares were up 5.8% in recent premarket activity Thursday.